Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Boston, Massachusetts. The company was originally incorporated as Precision Neuroscience NewCo, Inc. before changing its name in October 2022. Rapport focuses on discovering and developing small molecule medicines to treat central nervous system disorders, representing a relatively young entrant in the competitive biotechnology sector with a specialized focus on neurological conditions.

Based on the available financial data, Rapport Therapeutics has demonstrated consistent progress in advancing its clinical pipeline since its 2022 incorporation. The company successfully completed what appears to be a significant financing round, evidenced by the substantial increase in total assets from $31.6 million in 2022 to $314.9 million by the end of 2024. This capital infusion has enabled accelerated research and development activities, reflected in the increasing operational cash burn from $3.2 million in 2022 to over $20 million quarterly by 2025. The company's strategic focus has remained consistent across its three main therapeutic platforms: TARPγ8-targeted treatments for epilepsy and CNS disorders, and nicotinic acetylcholine receptor programs for pain and hearing disorders. The escalating research and development expenses suggest active clinical trial advancement, particularly for their lead candidate RAP-219. The maintenance of a strong balance sheet with minimal debt indicates management's focus on preserving financial flexibility to fund clinical operations through multiple development milestones. Recent quarters show stabilizing cash burn rates, suggesting the company may be reaching more predictable clinical trial execution phases. The preservation of substantial cash reserves while maintaining aggressive development timelines indicates strategic preparation for potential partnership discussions or additional clinical program expansions as key data readouts approach.